[{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"EastHORN Clinical Services | MLM Medical Labs | ALS Czech Republic | PCG Clinical Services","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Alpha Ketoanalogue","moa":"Amino acid metabolism","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fresenius Kabi AB Brunna \/ EastHORN Clinical Services | MLM Medical Labs | ALS Czech Republic | PCG Clinical Services","highestDevelopmentStatusID":"7","companyTruncated":"Fresenius Kabi AB Brunna \/ EastHORN Clinical Services | MLM Medical Labs | ALS Czech Republic | PCG Clinical Services"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sodium Acetate","moa":"Carbonic anhydrase-1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1; Amidophosphoribosyltransferase; Glutamine synthetase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Carbohydrate","year":"2018","type":"Inapplicable","leadProduct":"Lactulose","moa":"Evolved beta-galactosidase subunit alpha","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Carbohydrate","year":"2016","type":"Inapplicable","leadProduct":"Lactulose","moa":"Evolved beta-galactosidase subunit alpha","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Quintiles Inc","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AB Brunna \/ Quintiles Inc"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ganirelix","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Smofkabiven","moa":"Homeostasis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Fresenius Kabi AB Brunna \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AB Brunna \/ Parexel"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Smofkabiven","moa":"Homeostasis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Fresenius Kabi AB Brunna \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AB Brunna \/ Parexel"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Smofkabiven E","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Smofkabiven Extra Nitrogen","moa":"Homeostasis","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Smofkabiven Extra Nitrogen","moa":"Homeostasis","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oil","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Smoflipid","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Smoflipid","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Smoflipid","moa":"Homeostasis","graph1":"Undisclosed","graph2":"Phase III","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"HES 130","moa":"Plasma volume","graph1":"Nephrology","graph2":"Phase III","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"B. Braun Medical | European Society of Anaesthesiology and Intensive Care","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Carbohydrate","year":"2017","type":"Inapplicable","leadProduct":"Hydroxyethyl Starch","moa":"Plasma volume","graph1":"Hematology","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ B. Braun Medical | European Society of Anaesthesiology and Intensive Care","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ B. Braun Medical | European Society of Anaesthesiology and Intensive Care"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"B. Braun Medical | European Society of Anaesthesiology and Intensive Care","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Carbohydrate","year":"2017","type":"Inapplicable","leadProduct":"Hydroxyethyl Starch","moa":"Plasma volume","graph1":"Hematology","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ B. Braun Medical | European Society of Anaesthesiology and Intensive Care","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ B. Braun Medical | European Society of Anaesthesiology and Intensive Care"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Carbohydrate","year":"2012","type":"Inapplicable","leadProduct":"Hydroxyethyl Starch","moa":"Plasma volume","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cord Blood Cell","moa":"Progenitor cell","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"8","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"MALAYSIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Levobupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"medac","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Fish Oil Triglyceride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"8","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"HONG KONG","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Fresubin Fibre","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"High Protein Ons","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"High Protein Ons","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Carbohydrate","year":"2011","type":"Inapplicable","leadProduct":"Hydroxyethylstarch","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Intestamin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ketoanalogues Of Essential Amino Acids","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Nutritional Support Program","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Volulyte","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"MEXICO","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AB Brunna \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Fresubin Supportan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Fresenius Kabi AB Brunna
Details :
Fresubin Supportan is a Dietary Supplement drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Details :
Smoflipid is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Child Nutrition Disorders.
Details :
Tyenne (tocilizumab biosimilar) is a recombinant humanized monoclonal antibody targeting IL-6R, which specifically binds to sIL-6R and mIL-6R and inhibits signaling mediated by sIL-6R or mIL-6R. It is approved for the treatment of RA, sJIA, and CRS.
Details :
Ganirelix Acetate Injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Details :
Diazepam Injection is a ready-to-administer prefilled syringes which is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
Details :
Lidocaine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Details :
Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in 200 mg per 20 mL single-dose vials.
Details :
Idacio® (adalimumab), is a tumor necrosis factor (TNF) blocker and a biosimilar to Humira®. Adalimumab is a monoclonal antibody that binds TNFα and blocks its general cytokine effects.
Details :
Pralatrexate injection is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).